[ad_1]
Like every Thursday, the journalist Pascale Fuentes brings us the latest news about the coronavirus pandemic in Chile and the world. On this occasion, with very good news for our country.
And it is that after months of work, in a couple of weeks phase 3 testing will begin in Chile of two vaccines for the disease: Sinovac and Janssen. This after ISP authorized the start of the corresponding clinical trials.
The global picture indicates that 151 vaccines are in the preclinical stage, but 41 additional candidates are in the clinical stage. Of these 41, there are 10 that are in stage 3, that is, in clinical trials.
: ISP approves clinical trials of two vaccines against coronavirus: “Chile can and should participate in these studies” Read more
Regarding the Chinese Sinovac Biotech, it will be tested in the country through its two doses in a total of 14 days. In the case of Janssen, a Belgian subsidiary of the Johnson & Johnson company, it is also two doses, but the second will be given 56 days after the first dose.
About the vaccine Oxford-AstraZeneca, is still awaiting authorization from the ISP.
The Minister of Health, Enrique Paris, commented that “This is a very important milestone. Chile can and should participate in all these clinical phase 3 studies to approve, study, and hopefully move forward with the development of these vaccines.”
NUMBER OF VOLUNTEERS AND REQUIREMENTS
Sinovac will have 3,000 volunteers. Several of them will be health workers. In the case of Janssen, there will also be 3,000 volunteers, but there are conversations with offices in San Bernardo, Colina and even the Exequiel González Cortés Hospital.
The doctor Miguel O’Ryan, from the Institute of Biomedical Sciences of the University of Chile, assures that he hopes that the trials will begin in two or three more weeks.
As for the requirements for volunteers, they are required to have an age ranging between 18 and 59 years, but pregnant women, those who have had COVID-19 and immunosuppressed people are excluded.
Each vaccinated patient will be monitored by the ISP, a stage in which the effects on the population will be evaluated.
Heriberto García, director (S) of the ISP, comments on the importance of this process: “This surveillance is super important because that way we can know if the vaccine is better, or if there is a greater risk.”
Follow-up can last up to two years.
IT MAY INTEREST YOU
[ad_2]
